Formulated Delivery of Enzyme/Pro-Drug and Cytokine Gene Therapy to Promote Immune Reduction of Treated and Remote Tumors in Mouse Models of Prostate Cancer
Abstract
Prostate cancer is the second highest cause of cancer death in Western society men. Early stages are treatable, but late stage disease is incurable with palliative care the only option. Purpose: We will use a combination of gene therapy approaches to target prostate cancer locally and in other organs (metastases). Gene directed enzyme/pro-drug therapy (GDEPT) is delivered in the prostate. This kills cancer cells and generates an immune reaction, To augment this immune response, and reduce metastatic tumor growth, locally delivered cytokine gene therapy, is injected with the GDEPT.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2003
- Accession Number
- ADA420157
Entities
People
- Gerald W. Both
- P. L. Molloy
- Pamela J. Russell
- T. Lockett
Organizations
- University of New South Wales